Key facts
- Vesper Bio’s last known valuation is $6.3M (Dec 2017).
- It has raised $4.9M; the latest was Later Stage VC ($2.5M) in Nov 2025.
- Notable investors include Aarhus University, Alzheimers Drug Discovery Foundation, Michael J. Fox Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Vesper Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Vesper Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vesper Bio
Operator of a biotechnology company intended to provide treatment for diabetes and other metabolic diseases such as obesity. The company helps to control sugar levels in the body and has the potential to treat diabetes, enabling patients to begin their treatment more quickly and resulting in a higher likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2010
- Employees
- 11
- Website
- vesperbio.com/
- Ownership
- Privately Held (backing)
Vesper Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesper Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesper Bio in its N-PORT filings yet. We sweep new filings monthly.